Class 2 Recall on Co-Amoxiclav 125 Mg/31.25 Mg/5 Ml & 25 Mg/62.5 Mg/5 Ml Powder For Oral Suspension

Recalls and Alerts

Class 2 Recall

Class 2 Recall on Co-Amoxiclav 125 Mg/31.25 Mg/5 Ml & 25 Mg/62.5 Mg/5 Ml Powder For Oral Suspension

Sandoz Ltd. have been notified of a potential packaging problem relating to poor seal adherence which could cause clumping of the powder within the bottle. A poor bottle seal could lead to degradation of the clavulanic acid within the powder and could potentially render the product ineffective..

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP Code	Product Description	Supplier	Affected Batch
1086271	CO-AMOXICLAV SF 125/31.25MG	SANDOZ LTD	HT6202 HT7923
1117290	CO-AMOXICLAV 31/125MG/5ML	SANDOZ LTD	HT6202 HT7923
1086289	CO-AMOXICLAV 250/62MG	SANDOZ LTD	HT6202 HT7923
1117308	CO-AMOXICLAV SF 250/62.5MG	SANDOZ LTD	HT6202 HT7923

For enquiries relating to stock returns please contact Sandoz Limited Customer Services on 01276 698607 or email sales.sandoz-gb@sandoz.com

For Medical information enquiries, please contact Sandoz Medical Information Team on 01276 698101or email sandozgb@EU.propharmagroup.com

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

If you have any questions, then please contact your local Service Centre Customer Services team.